Prothrombin complex concentrate
| Combination of |
| Factor II |
Blood clotting factor |
| Factor VII |
Blood clotting factor |
| Factor IX |
Blood clotting factor |
| Factor X |
Blood clotting factor |
| Clinical data |
| Trade names |
Beriplex, Octaplex, Kcentra, others |
| AHFS/Drugs.com |
Monograph |
Routes of
administration |
injection |
| ATC code |
|
| Legal status |
| Legal status |
- In general: ℞ (Prescription only)
|
| Identifiers |
| Synonyms |
factor IX complex |
| CAS Number |
|
Prothrombin complex concentrate (PCC), also known as factor IX complex, is a medication made up of blood clotting factors II, IX, and X.[1] Some versions also contain factor VII.[2] It is used to treat and prevent bleeding in hemophilia B if pure factor IX is not avaliable.[1][3] It may also be used in those with not enough of these factors due to other reasons such as warfarin therapy.[3] It is given by slow injection into a vein.[1]
Common side effects include allergic reactions, headache, vomiting, and sleepiness.[1][4] Other serious side effects include blood clots which may result in a heart attack, stroke, pulmonary embolism, or deep vein thrombosis.[4] Antibodies may form after long term use such that future doses are less effective.[3]
Prothrombin complex concentrate came into medical use in the 1960s.[5] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[6][7] It is made from human plasma.[4] A version that is made by recombinant methods which only contains factor IX is also avaliable.[8] In the United States a dose of PCC costs about 900 USD.[9] A number of different formulations are available globally.[10]
Contents
- 1 Medical uses
- 2 Contraindications
- 3 Chemistry
- 4 History
- 5 References
- 6 Further reading
Medical uses
PCC reverses the effects of warfarin and other vitamin K antagonist anti-coagulants and is used in cases of significant bleeding in patients with a coagulopathy (INR > 8.0, prolonged prothrombin time). It is also used when such a patient must undergo an emergency operation treatment.[11] Other indications include a deficiency of one of the included clotting factors, either congenital or due to liver disease, and hemophilia.[11] Several guidelines, including American College of Chest Physicians,[12] recommend PCC for warfarin reversal in patients with serious bleed.[13][14][15]
Contraindications
Platelet factor 4 can cause heparin-induced thrombocytopenia.
The package insert states that PCC is contraindicated in patients with disseminated intravascular coagulation, a pathological activation of coagulation,[16] because giving clotting factors would only further fuel this process. However, if the PCC is given because factor levels are low, it can restore normal coagulation. As PCC products contain heparin, they are contraindicated in patients with heparin-induced thrombocytopenia.[16]
Chemistry
PCC contains a number of blood clotting factors. Typically this includes factor II, IX, and X.[1] Some versions also contain factor VII, protein C, and protein S.[2] Heparin may be added to stop early activation of the factors.[2]
History
The U.S. Food and Drug Administration (FDA) announced its approval of Kcentra on April 30, 2013. The FDA approved Kcentra's orphan drug status in December 2012.[17]
References
- ^ a b c d e WHO Model Formulary 2008 (PDF). World Health Organization. 2009. pp. 259–260. ISBN 9789241547659. Retrieved 8 December 2016.
- ^ a b c Perkins, John C. (2014). Hematology/Oncology Emergencies, An Issue of Emergency Medicine Clinics of North America,. Elsevier Health Sciences. p. 720. ISBN 9780323320290.
- ^ a b c British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 171. ISBN 9780857111562.
- ^ a b c "Factor IX (Human), Factor IX Complex (Human)". The American Society of Health-System Pharmacists. Retrieved 8 December 2016.
- ^ Besa, Emmanuel C. (1992). Hematology. Lippincott Williams & Wilkins. p. 276. ISBN 9780683062229.
- ^ "19th WHO Model List of Essential Medicines (April 2015)" (PDF). WHO. April 2015. Retrieved May 10, 2015.
- ^ The selection and use of essential medicines: Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). (PDF). WHO. 2015. p. 510. ISBN 9789240694941. Retrieved 8 December 2016.
- ^ "Factor IX (Recombinant)". The American Society of Health-System Pharmacists. Retrieved 8 December 2016.
- ^ Murray, Michael J.; Rose, Steven H.; Wedel, Denise J.; Wass, C. Thomas; Harrison, Barry A.; Mueller, Jeff T. (2014). Faust's Anesthesiology Review: Expert Consult (4 ed.). Elsevier Health Sciences. p. 543. ISBN 9781437703672.
- ^ Miller, Ronald D.; Eriksson, Lars I.; Fleisher, Lee A.; Wiener-Kronish, Jeanine P.; Cohen, Neal H.; Young, William L. (2014). Miller's Anesthesia (8 ed.). Elsevier Health Sciences. p. 1892. ISBN 9780323280112.
- ^ a b Haberfeld, H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Cofact.
- ^ "ACCP 2012 guidelines: 'Evidence-Based Management of Anticoagulant Therapy, Section 9.3 Treatment of Anticoagulant-Related Bleeding'". Chest Journal.
- ^ Haemostasis and Thrombosis Task Force for the British Committee for Standards in Haematology. Guidelines on oral anticoagulation: 3rd edition. Br J Haematol. 1998;101:374-387.
- ^ Baker, R. I.; Coughlin, P. B.; Gallus, A. S.; Harper, P. L.; Salem, H. H.; Wood, E. M.; Warfarin Reversal Consensus, G. (2004). "Warfarin reversal: Consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis". The Medical journal of Australia. 181 (9): 492–497. PMID 15516194.
- ^ Palareti, G. (1998). "A guide to oral anticoagulant therapy. Italian Federation of Anticoagulation Clinics". Haemostasis. 28 Suppl 1: 1–46. PMID 9820837.
- ^ a b Kcentra Prescribing Information
- ^ "Kcentra, from CSL Behring, Receives FDA Approval for Use in Warfarin Reversal in Patients Undergoing Surgery". CSL Behring. 13 December 2013.
Further reading
- Pabinger, I.; Brenner, B.; Kalina, U.; Knaub, S.; Nagy, A.; Ostermann, H.; Beriplex P/N Anticoagulation Reversal Study Group (2008). "Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: A prospective multinational clinical trial". Journal of Thrombosis and Haemostasis. 6 (4): 622–631. PMID 18208533. doi:10.1111/j.1538-7836.2008.02904.x.
- Bruce, D.; Nokes, T. J. (2008). "Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: Experience in a large tertiary hospital". Critical Care. 12 (4): R105. PMC 2575594 . PMID 18706082. doi:10.1186/cc6987.
|
Antihemorrhagics (B02)
|
Antihemorrhagics
(coagulation) |
| Systemic |
| Vitamin K |
- Phytomenadione (K1)
- Menadione (K3)
|
Coagulation
factors |
- intrinsic: IX/Nonacog alfa
- VIII/Moroctocog alfa/Turoctocog alfa
- extrinsic: VII/Eptacog alfa
- common: X
- II/Thrombin
- I/Fibrinogen
- XIII/Catridecacog
- combinations: Prothrombin complex concentrate (II, VII, IX, X, protein C and S)
|
Other
systemic |
- Etamsylate
- Carbazochrome
- Batroxobin
- thrombopoietin receptor agonist (Romiplostim
- Eltrombopag)
|
|
| Local |
- Absorbable gelatin sponge
- Oxidized cellulose
- Tetragalacturonic acid hydroxymethylester
- Thrombin
- Collagen
- Calcium alginate
- Epinephrine/Adrenalone
|
|
| Antifibrinolytics |
- amino acids (Aminocaproic acid
- Tranexamic acid
- Aminomethylbenzoic acid)
serpins (Aprotinin
- Alfa1 antitrypsin
- C1-inhibitor
- Camostat)
|